Trade

with

ImmunoCellular Therapeutics Ltd
(Amex: IMUC)
AdChoices
0.6951
-0.0168
-2.36%
After Hours :
0.6950
-0.0001
-0.01%

Open

0.7026

Previous Close

0.7119

Volume (Avg)

181.68k (325.93k)

Day's Range

0.6900-0.7200

52Wk Range

0.6500-4.00

Market Cap.

42.17M

Dividend Rate ( Yield )

-

Beta

1.28

Shares Outstanding

60.67M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 0

    • Net Income

    • -8.80M

    • Market Cap.

    • 42.17M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.28

    • Forward P/E

    • -3.48

    • Price/Sales

    • -

    • Price/Book Value

    • 1.70

    • Price/Cash flow

    • -4.08

      • EBITDA

      • -8.75M

      • Return on Capital %

      • -33.90

      • Return on Equity %

      • -37.81

      • Return on Assets %

      • -33.90

      • Book Value/Share

      • 0.41

      • Shares Outstanding

      • 60.67M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 3.50

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -0.20

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 0.00

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 23.73

              • 2.92

              • Quick Ratio

              • 22.87

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.10

              • 2.21

              • Book Value/Share

              • 0.41

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -4.50

                • 277.78

                • P/E Ratio 5-Year High

                • -25.30

                • 634.30

                • P/E Ratio 5-Year Low

                • -3.86

                • 124.82

                • Price/Sales Ratio

                • -

                • 9.35

                • Price/Book Value

                • 1.74

                • 8.50

                • Price/Cash Flow Ratio

                • -4.08

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -37.81

                    (-192.30)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -33.90

                    (-112.60)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -37.81

                    (-192.90)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • -

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -9.46M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -4.08
                  Ownership

                  Institutional Ownership

                  6.85%

                  Top 10 Institutions

                  5.44%

                  Mutual Fund Ownership

                  3.94%

                  Float

                  99.81%

                  5% / Insider Ownership

                  1.71%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Total Stock Mkt Idx

                  •  

                    904,721

                  • 0.00

                  • 1.49

                  • Vanguard Extended Market Index Fund

                  •  

                    738,722

                  • 4.88

                  • 1.22

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    177,102

                  • 0.00

                  • 0.29

                  • iShares Micro-Cap

                  •  

                    164,962

                  • 0.84

                  • 0.22

                  • Inversiones Copu SICAV

                  •  

                    90,066

                  • 0.14

                  • 0.16

                  • EB DL Non-SL Market Completion Fund

                  •  

                    80,222

                  • 766.70

                  • 0.13

                  • Bridgeway Ultra Small Company Market

                  •  

                    70,000

                  • 0.00

                  • 0.12

                  • Vanguard Growth and Income Fund

                  •  

                    47,092

                  • -13.42

                  • 0.08

                  • Vanguard Balanced Index Fund

                  •  

                    45,000

                  • 0.00

                  • 0.07

                  • Fidelity Spartan® Total Market Idx Fund

                  •  

                    41,923

                  • 0.00

                  • 0.07

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Group, Inc.

                  •  

                    1,651,843

                  • 0.00%

                  • 2.73

                  • Callan Capital, LLC

                  •  

                    393,912

                  • +462.73%

                  • 0.65

                  • Geode Capital Management, LLC

                  •  

                    219,025

                  • 0.00%

                  • 0.36

                  • BlackRock Fund Advisors

                  •  

                    173,242

                  • +2.94%

                  • 0.29

                  • D. E. Shaw & Co LP

                  •  

                    152,292

                  • +10.20%

                  • 0.25

                  • Susquehanna Financial Group, LLLP

                  •  

                    129,172

                  • -18.48%

                  • 0.21

                  • Northern Trust Investments, N.A.

                  •  

                    99,297

                  • -0.45%

                  • 0.16

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Slow Growth

                  Style

                  Small Growth

                  ImmunoCellular Therapeutics Limited was incorporated with the Secretary of State of Delaware on March 20, 1987 under the name Redwing Capital Corp. On November 2, 2006, it amended its Certificate of InCorporation to change its name t...moreo ImmunoCellular Therapeutics, Ltd. The Company is a clinical-stage biotechnology company developing immune-based therapies for the treatment of cancers, such as brain and ovarian. Immunotherapy is an approach to treating cancer in which a patient’s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company’s product candidate portfolio includes; ICT-107, ICT-121, and ICT-140. The ICT-107 is a DC-based vaccine targeting CSCs and cancer antigens that targets six different tumor-...moreassociated antigens that are found on patients’ tumor cells; at least four of the six antigens are highly expressed on CSCs. The therapeutic vaccine is used subsequent to conventional therapy or concomitantly with chemotherapy in patients with newly diagnosed GBM. On February 2014, ICT-107 was granted Orphan Drug status by the European Medicines Agency. The ICT-121 is a DC-based vaccine targeting CD133+ CSCs marker that is overexpressed in a wide variety of solid tumors, including ovarian, pancreatic, and breast cancers. The ICT-140 is a DC-based vaccine targeting CSCs and cancer antigens and targets seven different ovarian cancer antigens. Ovarian cancer usually spreads via local shedding into the peritoneal cavity followed by implantation on the peritoneum and via local invasion of bowel and bladder. The Company faces competition from the companies that have significantly more experience in undertaking preclinical testing and human clinical trials with new or improved therapeutic products and obtaining regulatory approvals of such products. The United States and other developed countries regulate the preclinical and clinical testing, manufacturing, labeling, storage, record-keeping, advertising, promotion, export, marketing and distribution of drugs and biologic products. The United States Food and Drug Administration, under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act and other federal statutes and regulations, regulate pharmaceutical and biologic products.lessless

                  Key People

                  Mr. Andrew Gengos

                  CEO/Director/President

                  Dr. John S. Yu,M.D.

                  Secretary/Chairman of the Board/Chief Scientific Officer/Director/Founder

                  David E. Fractor

                  CFO/Chief Accounting Officer/Vice President, Divisional

                  Dr. Rahul Singhvi

                  Director

                  Mr. Gary S. Titus

                  Director

                  • ImmunoCellular Therapeutics Ltd

                  • 23622 Calabasas Road

                  • Calabasas, CA 91302

                  • USA.Map

                  • Phone: +1 818 264-2300

                  • Fax: +1 818 224-5287

                  • imuc.com

                  Incorporated

                  1987

                  Employees

                  6

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: